Kabi Urges Caution And Patience On Subcutaneous Bortezomib Launch
As Firm Nears Pegfilgrastim Opportunities With Biosimilar Sales On Target
Fresenius Kabi’s Q1 call spanned its recent launch of a generic version of Takeda’s Velcade subcutaneous injectable to the company’s continued ambitions in biosimilars, with the German firm’s acquisition of a controlling stake in mAbxience scheduled to close by the middle of the year.
You may also be interested in...
Keeping Track: US FDA Novel Approvals Return With Xenpozyme, Spevigo Nods; Stimufend Survives COVID-19 Delays
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
AbbVie Focuses On Humira’s Formulary Positioning Ahead Of US Biosimilars
A year out from US competition to top-seller Humira, AbbVie is negotiating for formulary position alongside biosimilars. Analysts said success there could delay some patent cliff pain for the originator until 2024.
Amneal Scores Second US Biosimilar Approval With Avastin Rival
Amneal has received approval for its second US biosimilar in the form of the mAbxience-developed Alymsys rival to Avastin. The product represents just the third biosimilar version of bevacizumab to be approved in the US.